LTB 019

Drug Profile

LTB 019

Latest Information Update: 19 Sep 2003

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Sep 2003 No development reported - Phase-II for Chronic obstructive pulmonary disease (PO)
  • 12 Jul 2002 A clinical study has been added to the pharmacodynamics section
  • 31 Dec 2000 Phase-II clinical trials for Chronic obstructive pulmonary disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top